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Abstract: Previous studies have shown that changes in expression of the glycosaminoglycan, hyaluronan (HA) were 
associated with erosion in areas of post-mortem coronary artery liable to rupture. Angiogenesis is an important feature of 
ulcerating haemorrhagic plaques prone to rupture. HA is a glycosaminoglycan known to possess potent angiogenic prop-
erties on metabolism to oligosaccharides of HA (o-HA) in the presence of hyaluronidase (HYAL) enzymes. In this study, 
we have examined HA receptor and HYAL enzyme expression in a series of carotid artery specimens used as vascular 
transplants and exhibiting various stages of atherosclerotic lesions as determined by anatomo-pathology. Our results 
demonstrated dramatically increased expression of HYAL-1 in regions of inﬂ  ammation associated with complicated 
plaques. Receptor for HA-mediated motility (RHAMM), which is known to be important in transducing angiogenic signals 
in vascular endothelium, was strongly expressed on intimal blood vessels from complicated lesions but almost absent from 
other regions including adventitial vessels. Metabolism of HA, together with up-regulation of RHAMM in complicated 
plaque lesions might be partly responsible for over-production of leaky neovessels and predisposition to plaque rupture.
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Introduction
Myocardial infarction and stroke represent the second and third leading causes of death and disability 
in the Western world respectively. The majority of cases result from thrombosis or embolism following 
rupture of unstable coronary and carotid arterial plaques. Development of this pathology is thought to 
be as a consequence of a combination of a number of risk factors, including age, gender, hypertension, 
hyperlipidaemia, smoking, diabetes and infections. The atherosclerotic plaque is a dynamic structure 
that undergoes continuous remodeling of the extracellular matrix during development, and on which 
its structural integrity is dependent (Miguel et al. 2006). Lesions including phase 2 and upwards fol-
lowing endothelial injury are prone to rupture (Stary et al. 1995). Acute changes within the plaque 
including active matrix remodeling, intraplaque hemorrhage associated with vascularization and ﬁ  brous 
cap rupture are a prelude to the onset of clinical ischemic events, however, the mechanisms and activa-
tion processes leading to this are not fully understood. Angiogenesis occurs within vascular lesions, 
resulting in formation of a network of capillaries, which extend into the thickened intimal layer associ-
ated with atherosclerosis and inﬂ  ammation, and ultimately increasing susceptibility of the plaque to 
rupture (Moﬁ  di et al. 2002; Moulton, 2006; Krupinski et al. 2006). The identiﬁ  cation of plaque erosion 
sites rich in proteoglycan expression and associated with vessel occlusion without rupture of the ﬁ  brous 
plaque cap represents a novel pathophysiological basis for atherothrombosis (Kolodgie et al. 2002; 
Hennerici, 2004).
Hyaluronan (HA) is a non-sulphated linear glycosaminoglycan consisting of repeating units of 
(α,1–4)-D-glucuronic acid-(β,1–3)-N-acetyl-D-glucosamine. HA is found in its native state as a high 
molecular weight polymer (10
6 kDa) in the extracellular matrix of almost all animal tissues and in 
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signiﬁ  cant quantities in the skin (dermis and 
epidermis) and the brain (Slevin et al. 2006). 
Apart from its role as an inert viscoelastic lubri-
cant which is essential for healthy joint function 
(West and Kumar, 1991), HA has a crucial role 
in regulation of the angiogenic process. In par-
ticular, HA is a potent regulator of vascular 
endothelial cell (EC) function. Native high 
molecular weight HA (10
6 KDa) is synthesized 
by a family of enzymes called HA synthases 
(HAS), and is anti-angiogenic, inhibiting EC 
proliferation and migration (West and Kumar, 
1989; Deed et al. 1997) as well as capillary for-
mation in a 3D collagen gel model (Sattar et al. 
1994). Degradation products of speciﬁ  c size (3–10 
disaccharide units; o-HA) stimulate EC prolif-
eration, migration, sprout formation and result in 
angiogenesis in the chick chorioallantoic mem-
brane (Slevin et al. 2002, 1998; West et al. 1985). 
Generation of this ‘angiogenic’ o-HA, from the 
naturally occurring HA polymer is mediated by 
action of the endoglycosidase hyaluronidase 
(HYAL; Lokeshwar et al. 2001), in association 
with tissue damage, and inflammatory disease 
(West and Kumar, 1989). The biological func-
tions of HA/o-HA are thought to be initiated 
through cell surface receptors (particularly, 
CD44 and RHAMM (receptor for HA mediated 
motility)), resulting in signal transduction acti-
vation and ultimately cell mitogenesis. In vas-
cular EC, both CD44 (Nandi et al. 2000; Slevin 
et al. 1998) and RHAMM (Lokeshwar et al. 
2000), have been identified as potential targets 
for transduction of o-HA-induced mitogenesis. 
We have previously demonstrated that o-HA but 
not native HA induced up-regulation of the 
immediate early response genes c-jun, jun B, 
Krox 20, Krox 24 and c-fos in bovine aortic EC 
(BAEC) (Deed et al. 1997). Similarly, o-HA 
induced rapid CD44 dependent activation of 
PKC, Raf-1 kinase, MEK-1 and ERK1/2 result-
ing in mitogenesis in these cells (Slevin et al. 
2002).
Previous studies have demonstrated an increase 
in expression of hyaluronan in distinct regions of 
human post-mortem aortic atherosclerotic plaques 
(Kolodgie et al. 2002; Papakonstantinou et al. 
1998), although the size of the expressed mole-
cule was not determined. In this manuscript, we 
have investigated the expression of HA metabo-
lising enzymes and receptors for HA in a series 
of carotid artery transplants.
Methodology
Carotid artery transplants
Carotid specimens were obtained from dying patients, 
used for vascular transplants and exhibiting various 
stages of the atherosclerotic disease process (Phase 
I–V). Plaque pathology and characteristics including 
ulcerating, haemorrhagic or eroding regions was 
determined by anatomo-pathology (Table 1).
Western blotting
Antibodies to the HA receptors, TSG-6 and 
RHAMM as well as hyaluronidase 1 and 2 and HA 
synthase 1 and 2, were supplied by our collabora-
tors (Dr. Katalin Mikecz, Chicago, U.S.A., Dr. Eva 
Turley, Ontario, Canada, Professor Rashmin 
Savani, Philadelphia, U.S.A. and Dr. Evi Heldin, 
Uppsala, Sweden respectively). Their activities and 
speciﬁ  cities have been conﬁ  rmed previously in 
detail (AlQteishat et al. 2006 and references 
therein). Anti-CD44 was bought from Calbiochem 
(U.K.). Brieﬂ  y, tissue samples (50 mg) were lysed 
and protein separation carried out using SDS-
PAGE electrophoresis as described previously 
(Slevin et al. 1998). Blots were stained overnight 
at 4 °C with primary antibodies described above 
and (Sigma, 1:1000) used as a loading control. 
Protein concentration was estimated from the band 
intensity by densitometry. Results are not quantita-
tive and are used only to demonstrate differences 
in expression as a basis for selection of IHC 
analysis. All experiments were performed twice 
and a representative example is shown.
Immunohistochemistry
Cellular localization was examined by immuno-
histochemistry, The Avidin-Biotin-Peroxidase 
method (ABC Vectastain kit, Vector Laboratories, 
Peterborough, U.K.) was used for the qualitative 
demonstration of antigens in tissues. Antibodies 
described above were used at 1:50 dilution. 
De-parraﬁ  nised 5 µm sections were treated for 
10min in a boiling solution of concentrated citric 
acid (pH 6.0; Vector Laboratories) in a pressure 
cooker to unmask the antigens. Sections were 
stained with primary antibodies for 2h at RT, with 
the appropriate HRP-conjugated secondary anti-
body for 1h at RT, and then counterstained with 
haematoxylin. Negative control slides had the 
primary antibody replaced with PBS or the 363
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appropriate IgG pre-immune serum. Speciﬁ  city of 
the antibodies has been previously established 
(AlQteishat et al. 2006a and b).
Results
Complicated plaque regions 
expressed increased concentration
of HYAL-1
Weak expression of HYAL-1 was seen in Western 
blots of carotid transplants with no evidence of intra-
luminal plaques and in those with stable ﬁ  brous 
structures (Fig. 1a; e.g. B and F and Fig. 1b (i); B 
shown). In contrast, complicated plaque lesions 
showed higher expression of HYAL-1 (Fig. 1a; e.g. A 
and H), particularly in areas of inﬂ  ammation (Fig. 1b
(ii) and (iii); A and H shown respectively). HYAL-2 
was weakly expressed in normal looking arteries and 
no difference was seen in plaque lesions (data not 
included). Only weak expression of HAS1/2 was seen 
in both normal arteries and non-complicated/compli-
cated regions with no signiﬁ  cant differences in neoves-
sel rich/poor areas of intima (data not shown).
RHAMM receptor was identiﬁ  ed
in neovessels from complicated 
plaque lesions
RHAMM receptor was weakly expressed in normal 
looking arteries as shown by Western blots (Fig. 2a; e.g. 
B and F). IHC conﬁ  rmed a general lack of expression 
even in adventitial blood vessels (Fig. 2b (i); B 
shown). Carotid arteries with complicated lesions 
demonstrated increased staining in Western blots, and 
strong localization around plaque intimal neovessels 
(Fig. 2b (ii) and (iii); E shown). The presence of 
intimal blood vessels was conﬁ  rmed by staining serial 
sections with antibodies to CD105 which stained 
active endothelial cells (Fig. 2b (iv); E shown). No 
differences in CD44 or TSG-6 expression were found 
(data not included).
Discussion
New blood vessels may have an active role in 
plaque metabolic activity and actively promote its 
growth beyond the critical limits of diffusion from 
the artery lumen. Later in the progression of the 
disease, the inherent weakness of newly forming 
blood vessels could result in development of intra-
plaque haemorrhage and instability (Moﬁ  di et al. 
2001; Herrmann et al. 2006; Krupinski et al. 2006). 
In this study, we have demonstrated that HYAL-1, 
which can depolymerise n-HA to angiogenic frag-
ments, was increased in inﬂ  ammatory complicated 
plaque regions. Previous studies have shown that 
HA was up-regulated in atherosclerotic lesions of 
apoE deﬁ  cient mice, although the molecular weight 
was not determined (Cuff et al. 2001). In stable 
lesions, the ﬁ  brous cap is enriched with ECM 
molecules including versican and biglycan, which 
promote stability, viscoelasticity and inhibit vas-
cular growth.
Rupture sites, however, have almost complete 
absence of ECM, in particular n-HA, possibly due 
to increased expression of matrix metalloprotein-
ases (Kolodgie et al. 2002). It has been suggested 
that loss of n-HA corresponds with decreased 
Table 1. Anatomo-pathological characteristics of plaques used in study.
 Sex  Age  Plaque  description
A  m  69  Advanced, Complicated with thrombosis, inﬂ  ammation +++, angiogenesis,
      active, focal necrosis, calciﬁ  cation
B  m  68  Small plaque, lipidic core, inﬂ  ammation ++
C  m  79  Advanced Complicated with thrombosis, rupture, calciﬁ  cation, inﬂ  ammation +++, 
     angiogenesis,  active
D  m  75  Normal, type I, thickenning of intima 
E  f  86  Advanced, active, lipidic core, inﬂ  ammation +++, angiogenesis, focal necrosis
F  f  76  Normal, thickenning of intima
G  m  56  Normal, thickenning of intima
H  m  74  Advanced, complicated, calciﬁ  ed plaque, inﬂ  ammation +, angiogenesis
I  m  70  Advanced, active plaque, lipidic core, inﬂ  ammation +++, angiogenesis, focal 
      necrosis, small calciﬁ  cations
J  m  82  Small plaque, calciﬁ  cation, inﬂ  ammation ++, angiogenesis, erosion
K  m  66  Advanced, complicated plaque, calciﬁ  cation, inﬂ  ammation +++, angiogenesis, 
      rupture, lipidic core364
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Figure 1. HYAL-1 expression was increased in complicated plaque regions. (A) Western blots showing relative expression of HYAL-1
in a series of carotid arteries obtained at endarterectomy (Table 1). Highest expression was seen in complicated plaques (A and H; Table 1). 
(B) IHC showed only weak expression of HYAL-1 in the media of normal looking vessels (i; B), but strong expression in the intimal neovessels 
(ii; A) and inﬂ  ammatory regions (iii; H) of complicated plaques.
integrity of the ﬁ  brous cap. Plaque erosion sites 
are distinct from rupture sites in that they contain 
many more SMC and ECM. These sites also tend 
to progress to thrombi. A signiﬁ  cant increase in 
HA was found at the erosion site and at the 
plaque-thrombus interface of eroded vasculature, 
although the molecular size was not determined. 
Administration of either high molecular weight or 365
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Figure 2. RHAMM expression was increased in complicated plaque regions. (A) Western blots showing relative expression of RHAMM 
in carotid arteries obtained at endarterectomy (Table 1). Highest expression was seen in complicated plaques (C and E; Table 1), but 
RHAMM was also expressed in non-complicated plaques (D and G). (B) IHC showed only weak expression of RHAMM in the media of 
normal looking vessels (I, B), but strong expression in the intimal neovessels (ii and iii; E) of complicated plaques. Endothelial cells of 
neovessels in complicated plaques demonstrated staining of CD105 (iv; E).366
Krupinski et al
Biomarker Insights 2007:2
angiogenic fragments (4–16 dissacharides) of HA 
reduced SMC proliferation and neointima forma-
tion in rats after balloon catheter injury suggesting 
a beneﬁ  cial effect on developing lesions (Chajara 
et al. 2003). In this study, we found no evidence 
of increased HA synthesis in complicated angio-
genic lesions.
In this paper, we show for the ﬁ  rst time that the 
RHAMM receptor is over-expressed in neovessels 
from complicated plaque regions, and therefore 
might be responsible for enhanced endothelial cell 
activation via intracellular signal transduction fol-
lowing binding of o-HA. Evidence has shown that 
changes in expression of HA and its receptors occur 
concomitantly with transformation of stable to 
unstable arterial plaques. Increased expression of 
HA together with its receptor CD44 were found in 
rupture-prone areas in post-mortem coronary arter-
ies (Farb et al. 2004), whilst increased expression 
of CD44 was found in atheromatous plaque 
microvessels, and treatment with anti-CD44/
CD44v6 antibodies, reduced EC proliferation 
in vitro (Krettek et al. 2004). In contrast, we did not 
ﬁ  nd any difference in expression of CD44 between 
non-complicated and complicated carotid plaques.
In summary, although n-HA is a strong inhibitor 
of blood vessel growth, and for example, treatment 
of experimental balloon catheter vascular injury 
was associated with an inhibition of neointimal 
formation (Savani and Turley, 1995), it is possible 
that at injury sites, enzymatic or oxidative/nitrative 
breakdown of n-HA into smaller fragments, 
stimulates the growth of new vessels and could 
encourage plaque haemorrhage and rupture. Thus, 
changes in metabolism of HA, together with cel-
lular receptor expression might be responsible for 
key dynamic changes in plaque vulnerability.
Rupture or thrombosis of unstable atherosclerotic 
plaques in the coronary arteries is a major cause of 
heart infarction. Development of this disease occurs 
over a period of decades, during which time, the 
arterial tissue undergoes a remodeling process mak-
ing it susceptible to rupture. Hyaluronan is an 
important component of the arterial matrix, and may 
be intimately associated with this process.
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